Rossix AB

Werfen is a global in vitro diagnostics company operating directly in over 30 countries and through distributors in more than 100 territories. The company develops, manufactures, and commercializes diagnostic systems, reagents, software, and services across hemostasis, acute care diagnostics, transfusion, autoimmunity, transplant, immunoassay, and clinical chemistry. Werfen's hemostasis portfolio includes in vitro diagnostic systems and reagents for diagnosing and guiding treatment of thrombotic and bleeding disorders. The acute care diagnostics line provides integrated whole-blood testing solutions for cardiovascular operating rooms, catheterization laboratories, intensive care units, and emergency departments. The transfusion division offers manual and automated solutions with serology reagents, fully automated instrumentation, data management software, and molecular products for donor-recipient compatibility. The autoimmunity segment delivers reagents and lab automation for diagnosing and monitoring autoimmune diseases. Transplant products feature molecular and antibody-based HLA assays and software for pretransplant compatibility determination and post-transplant monitoring. Clinical chemistry solutions serve chemistry and pharma-toxicology laboratories. Werfen also recently completed the acquisition of Omixon, a Budapest-based company specializing in next-generation sequencing technologies for transplant diagnostics. The company maintains a technology center in Bedford, Massachusetts, expanded in December 2024. Werfen's solutions are designed to improve patient care quality, reduce laboratory costs, ensure regulatory compliance, and enhance operational efficiency across clinical laboratory and acute care hospital settings.